Cargando…
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
Amino acid substitutions and deletions in the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants can reduce the effectiveness of monoclonal antibodies (mAbs). In contrast, heterologous polyclonal antibodies raised against S protein, through the recognition of mult...
Autores principales: | Vanhove, Bernard, Marot, Stéphane, So, Ray T., Gaborit, Benjamin, Evanno, Gwénaëlle, Malet, Isabelle, Lafrogne, Guillaume, Mevel, Edwige, Ciron, Carine, Royer, Pierre-Joseph, Lheriteau, Elsa, Raffi, François, Bruzzone, Roberto, Mok, Chris Ka Pun, Duvaux, Odile, Marcelin, Anne-Geneviève, Calvez, Vincent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634597/ https://www.ncbi.nlm.nih.gov/pubmed/34868003 http://dx.doi.org/10.3389/fimmu.2021.761250 |
Ejemplares similares
-
Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants
por: Vanhove, Bernard, et al.
Publicado: (2023) -
LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation
por: Rousse, Juliette, et al.
Publicado: (2023) -
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study
por: Gaborit, Benjamin, et al.
Publicado: (2021) -
Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial
por: Gaborit, Benjamin, et al.
Publicado: (2023) -
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
por: Gaborit, Benjamin, et al.
Publicado: (2021)